Logo

Amgen and UCB's Evenity (romosozumab) Receive EC's Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Share this

Amgen and UCB's Evenity (romosozumab) Receive EC's Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Shots:

  • The EC has granted MAA to Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture- following the CHMP’s positive opinion received in Oct’2019
  • Evenity is the first osteoporosis therapy to be approved by EC since 2010 and the MAA will be valid in EU and EEA- EFTA states (Norway- Iceland and Liechtenstein)
  • Evenity is a bone-forming mAb with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss) with its expected availability in EEA in H1’20

Click here to­ read full press release/ article | Ref: Amgen | Image: STAT News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions